AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12568205
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg for 8 weeks
Trial: 12568205
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg daily after washout
Trial: 9525448
Drug: Topical steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroids (200 microg fluticasone propionate twice daily; n = 16)
Trial: 9525448
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo nasal spray (n = 17)
Trial: 8580622
Drug: IgA antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgA antibodies to BSA
Trial: 8580622
Drug: IgG antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibodies to BSA
Trial: 8580622
Drug: IgA antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgA antibodies to ovalbumin
Trial: 8580622
Drug: IgG antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibodies to ovalbumin
Trial: 8580622
Drug: IgA antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgA antibodies to beta-lactoglobulin
Trial: 8580622
Drug: IgA antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgA antibodies to cow's milk
Trial: 30168004
Drug: Evocalcet 1-20
RxNorm normalized name: evocalcet
DrugBank: Evocalcet (DB12388)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Evocalcet 1-20 mg (single dose)
Trial: 30168004
Drug: Evocalcet 6
RxNorm normalized name: evocalcet
DrugBank: Evocalcet (DB12388)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Evocalcet 6 and 12 mg (multiple doses)
Trial: 30168004
Drug: Evocalcet up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evocalcet up to 12 mg (multiple doses)
Trial: 30168004
Drug: Evocalcet up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evocalcet up to 20 mg (single dose)
Trial: 24560135
Drug: Micronised fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronised fenofibrate 267 mg daily
Trial: 20636275
Drug: SQV/ritonavir (SQV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQV/ritonavir (SQV/r) 1000 mg/ritonavir 100 mg BID
Trial: 20636275
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (habitual treatment)
Trial: 7595738
Drug: Interferon alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐2a (IFN‐alpha 2a) 20 x 10(6) U/m2 administered three times each week for 12 weeks
Trial: 2147842
Drug: Enoximone (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (total dose of 1.5 mg/kg)
Trial: 2147842
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three drugs (Enoximone, Dobutamine, Sodium nitroprussiate)
Trial: 31027300
Drug: High fiber
RxNorm normalized name: High Fiber Gummies Soft Chew
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fiber cereal (90 g, 11 g fiber/90 g) consumed at Sohor for 20 consecutive days
Trial: 31027300
Drug: High fiber
RxNorm normalized name: High Fiber Gummies Soft Chew
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fiber cereal (90 g, 11 g fiber/90 g)
Trial: 27809609
Drug: Control Device:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Device: FDA‐cleared syringe driver with FDA‐cleared infusion set
Trial: 15776301
Drug: alpha‐GST concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐GST concentrations (> 490 microg L(‐1))
Trial: 12081988
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT) with adjustment for postrandomization statin use
Trial: 7840322
Drug: Younger reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Younger reference subjects (< 33 years old) taking no supplement
Trial: 17892996
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of mononuclear bone marrow cells (mBMCs)
Trial: 16841333
Drug: alpha‐tocopherol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐tocopherol (400 IU/day) and beta‐carotene (30 mg/day) supplements
Trial: 12968238
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous administration of low‐dose fenoldopam (0.1‐0.3 microg/kg/min) during cardiopulmonary bypass and in the early postoperative period (group B)
Trial: 1623694
Drug: Niguldipine (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niguldipine (0.3, 0.6, and 0.9 mg intravenously; 8 and 16 mg orally)
Trial: 1623694
Drug: Nifedipine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (2 mg intravenously; 20 mg orally)
Trial: 6378555
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received preoperative systemic antibiotic prophylaxis
Trial: 29303212
Drug: Topical methylprednisolone
RxNorm normalized name: methylprednisolone Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical methylprednisolone cream
Trial: 25884010
Drug: NP001 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NP001 2 mg/kg
Trial: 25884010
Drug: NP001 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NP001 1 mg/kg
Trial: 15080830
Drug: Sublingual swallow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual swallow immunotherapy (SLIT)
Trial: 9429007
Drug: Homoeopathic medicine
RxNorm normalized name: Homoeopathic medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homoeopathic medicine
Trial: 3435119
Drug: Cefpimizole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpimizole (100 mg to 2000 mg)
Trial: 3435119
Drug: Cefpimizole (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpimizole (500 mg and 1000 mg twice-daily)
Trial: 27075708
Drug: Behavioral family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral family systems therapy‐diabetes (BFST‐D) via telehealth
Trial: 27075708
Drug: Traditional (Clinic)
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional (Clinic) treatment
Trial: 24369254
Drug: INFα‐2b monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INFα‐2b monotherapy (5×10(6), three times a week)
Trial: 24369254
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with entecavir (0.5 mg/day) plus adefovir (10 mg/day)
Trial: 16791523
Drug: Preparing for
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparing for the Drug Free Years program (PDFY)
Trial: 10920066
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 300 mg/d
Trial: 10920066
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 600 mg/d
Trial: 10920066
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 1200 mg/d
Trial: 6531951
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of trivalent influenza subunit vaccine (7 micrograms per dose)
Trial: 27241710
Drug: Levodopa 100
RxNorm normalized name: levodopa 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa 100 mg/carbidopa 25 mg
Trial: 18544002
Drug: Parecoxib 40
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib 40 mg intravenously every 12 hours for 48 hours
Trial: 18544002
Drug: Dipyrone 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 2.5 g intravenously intraoperatively, followed by 1 g every 6 hours for 48 hours
Trial: 18544002
Drug: Cumulative piritramide
RxNorm normalized name: piritramide
DrugBank: Piritramide (DB12492)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative piritramide administration
Trial: 11528495
Drug: Fruit juice
RxNorm normalized name: Fruit Juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruit juice (1 l per day)
Trial: 11528495
Drug: Fruit-vegetable-concentrate (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruit-vegetable-concentrate (30 ml per day)
Trial: 9371896
Drug: Zolmitriptan doses
RxNorm normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zolmitriptan doses > or = 2.5 mg
Trial: 9371896
Drug: Zolmitriptan (second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan (second dose)
Trial: 9371896
Drug: Zolmitriptan doses
RxNorm normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zolmitriptan doses < or = 2.5 mg
Trial: 1553930
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (4.2 g of omega-3 fatty acids per day)
Trial: 25242558
Drug: Ixekizumab 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab 120 mg subcutaneous every 4 weeks during OLE
Trial: 20075184
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (500 mg, intravenous)
Trial: 20075184
Drug: Haloperidol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (10 mg, intramuscular)
Trial: 12593521
Drug: BDP via
RxNorm normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP via metered-dose inhaler (MDI) 1,600 microg
Trial: 12593521
Drug: BDP suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP suspension for nebulization 1,600 microg
Trial: 12593521
Drug: BDP suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP suspension for nebulization 3,200 microg
Trial: 12165579
Drug: Single remote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single remote course of antenatal corticosteroids (two 12‐mg doses of betamethasone)
Trial: 12165579
Drug: Weekly courses
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly courses of antenatal corticosteroids
Trial: 7789043
Drug: Clonidine (infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (infusion rates of 16-2048 ng/min)
Trial: 6107587
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and oral disopyramide
Trial: 6652010
Drug: Morphine 5
RxNorm normalized name: ethylmorphine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 5 mg into the extradural space
Trial: 29774465
Drug: 4000 mg
RxNorm normalized name: talc 4000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4000 mg myo-inositol plus 400 mcg folic acid (MI treatment)
Trial: 29774465
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg D-chiro-inositol plus 400 mcg folic acid (DCI treatment)
Trial: 29774465
Drug: 1100/27.6 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1100/27.6 mg myo/D-chiro-inositol plus 400 mcg folic acid (MI plus DCI treatment)
Trial: 29774465
Drug: 400 mcg
RxNorm normalized name: Biotin 400 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mcg folic acid (control treatment)
Trial: 27760402
Drug: CC-60 (21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-60 (21 mg/day carotenes)
Trial: 27760402
Drug: TRF-80 (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRF-80 (420 mg/day tocotrienol + 132 mg/day tocopherol)
Trial: 24923573
Drug: Thumbtack intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thumbtack intradermal (TI) needles (control)
Trial: 22836707
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi (50 min daily training for 6 months)
Trial: 8789545
Drug: Cetirizine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (30 mg daily for 5 days)
Trial: 8789545
Drug: Prednisolone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (20 mg daily for 5 days)
Trial: 1615546
Drug: Intravenous glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glycerol (500 ml of 10% glycerol in saline by intravenous infusion over 4 hours on 6 consecutive days)
Trial: 1615546
Drug: Saline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline treatment (placebo)
Trial: 8872694
Drug: Intramuscular glycopyrrolate
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular glycopyrrolate
Trial: 31143882
Drug: CC‐Cruiser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC‐Cruiser
Trial: 30241687
Drug: Pregabalin 300
RxNorm normalized name: pregabalin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 300 mg BID for 6 times
Trial: 30241687
Drug: Thioctic acid
RxNorm normalized name: Thioctic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thioctic acid 600 mg once daily for 3 times
Trial: 30241687
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pregabalin and thioctic acid
Trial: 24708735
Drug: Oral dose
RxNorm normalized name: Exactamed Oral Dose Syringe 35cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of 50,000 IU vitamin A
Trial: 20081227
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (cilostazol, thienopyridine, aspirin)
Trial: 20081227
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (thienopyridine, aspirin)
Trial: 20081227
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy and Dual therapy
Trial: 12052603
Drug: Intravaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal misoprostol moistened with 1 mL of 3% acetic acid solution
Trial: 12052603
Drug: Intravaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal misoprostol in dry tablet form
Trial: 10397281
Drug: Alcohol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.5 g/kg) in OC+ subjects
Trial: 10397281
Drug: Alcohol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.5 g/kg) in OC- subjects
Trial: 10397281
Drug: Alcohol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.5 g/kg) in both OC+ and OC- subjects
Trial: 10397281
Drug: Alcohol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.5 g/kg) in OC+ subjects during midcycle
Trial: 10397281
Drug: Alcohol (0.34-1.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.34-1.02 g/kg) in OC+ subjects (substudy)
Trial: 29627620
Drug: LUB 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LUB 12 μg
Trial: 29627620
Drug: LUB 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LUB 24 μg
Trial: 25252727
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of cefetamet sodium for IV infusion over 30 minutes
Trial: 25252727
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of cefetamet sodium for IV infusion over 30 minutes
Trial: 25252727
Drug: 2000 mg
RxNorm normalized name: bran 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg of cefetamet sodium for IV infusion over 30 minutes
Trial: 23949430
Drug: Dinaciclib 50
RxNorm normalized name: Dinaciclib
DrugBank: Dinaciclib (DB12021)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinaciclib 50 mg/m² given as a 2-h infusion every 21 days
Trial: 15858936
Drug: Nitroglycerin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (3 microg/kg) added to the cardioplegic solution
Trial: 15858936
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 microg/kg) added to the cardioplegic solution
Trial: 14503094
Drug: Amoxicillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanic acid for 10 days
Trial: 10374221
Drug: Estrogen-androgen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen-androgen therapy (0.625 mg esterified estrogens combined with 1.25 mg methyltestosterone)
Trial: 10374221
Drug: Estrogen-androgen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen-androgen therapy (1.25 mg esterified estrogens combined with 2.5 mg methyltestosterone)
Trial: 10374221
Drug: Estrogen-only therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen-only therapy (0.625 mg esterified estrogens)
Trial: 10374221
Drug: Estrogen-only therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen-only therapy (1.25 mg esterified estrogens)
Trial: 10374221
Drug: Estrogen-androgen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen-androgen therapy
Trial: 10374221
Drug: Estrogen-androgen treatment
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen-androgen treatment
Trial: 6345023
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy (group 2)
Trial: 18325516
Drug: Increasing doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing doses of E(2) from days 3 to 5 (group 1)
Trial: 18325516
Drug: No hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No hormonal treatment (group 2)
Trial: 18325516
Drug: Increasing doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing doses of E(2) for 15 days (group 3)
Trial: 17190528
Drug: Stimulant and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant and nonstimulant medications
Trial: 17190528
Drug: Long-acting medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting medications
Trial: 17190528
Drug: Negotiated trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negotiated trial of time off treatment
Trial: 9752283
Drug: Granisetron (Gra)
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron (Gra) 1 mg
Trial: 9752283
Drug: Ondansetron (Ond)
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron (Ond) 8 mg
Trial: 748488
Drug: Fluocinolone cream
RxNorm normalized name: fluocinolone Topical Cream
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluocinolone cream applied twice a day for five days
Trial: 748488
Drug: Inert carrier
RxNorm normalized name: inert ingredients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert carrier base applied twice a day for five days
Trial: 20716911
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of creatine (Cr)
Trial: 15231367
Drug: Methylprednisolone (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (16 mg for 4 weeks tapered to 4 mg for 4 months)
Trial: 10646895
Drug: L-carnitine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine treatment in tumour-bearing mice
Trial: 8958001
Drug: Ethanol (0.66
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.66 g ethanol/kg orally followed by 0.1 g ethanol/kg per h intravenously)
Trial: 8958001
Drug: Control (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (identical volumes of oral water and intravenous saline)
Trial: 9860036
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate 200 microg once daily
Trial: 8589159
Drug: Cefixime (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime (8 mg/[kg.d]; maximum 400 mg) once a day for 4 days
Trial: 8589159
Drug: Rifampin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (20 mg/kg; maximum, 600 mg) once a day for 4 days
Trial: 2283715
Drug: Cefdinir granules
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir granules at a dose of 3 mg/kg